Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ellen Townley

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
Journal of Graduate Medical Education|December 16, 2024
Diagnostic Stewardship Is Environmental StewardshipKristen Bastug, Ellen Townley, Laura Norton
The Pediatric Infectious Disease Journal|August 6, 2015
Safety, Pharmacokinetics and Efficacy of Dolutegravir in Treatment-experienced HIV-1 Infected Adolescents: Forty-eight-week Results from IMPAACT P1093Rolando M Viani, Carmelita Alvero, Terry Fenton, et al.
Antimicrobial Agents and Chemotherapy|July 18, 2002
Safety, pharmacokinetics, and pharmacodynamics of cyclodextrin itraconazole in pediatric patients with oropharyngeal candidiasisAndreas H Groll, Lauren Wood, Maureen Roden, et al.
AIDS (London, England)|May 20, 2024
Bridging dolutegravir clinical viral response across doses and formulations using model-based exposure-response analysis in pediatricsHardik Chandasana, Siobhán Hayes, Ann M Buchanan, et al.
Journal of the Pediatric Infectious Diseases Society|April 6, 2019
Long-Term Safety and Efficacy of Dolutegravir in Treatment-Experienced Adolescents With Human Immunodeficiency Virus Infection: Results of the IMPAACT P1093 StudyRolando M Viani, Theodore Ruel, Carmelita Alvero, et al.
Journal of Child and Adolescent Mental Health|November 17, 2024
Participant acceptability and clinician satisfaction of cognitive behavioural therapy and medication management algorithm compared with enhanced standard care for treatment of depression among youth with HIVEmily A Barr, Kristin Baltrusaitis, Betsy D Kennard, et al.
AIDS (London, England)|November 6, 2019
Pharmacokinetics and safety of a raltegravir-containing regimen in HIV-infected children aged 2-12 years on rifampicin for tuberculosisTammy Meyers, Pearl Samson, Edward P Acosta, et al.
Journal of the Pediatric Infectious Diseases Society|May 26, 2020
Pharmacokinetics and Safety of a Raltegravir-Containing Regimen in Children Aged 4 Weeks to 2 Years Living With Human Immunodeficiency Virus and Receiving Rifampin for TuberculosisPaul Krogstad, Pearl Samson, Edward P Acosta, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 15, 2022
Forty-Eight Week Outcomes of a Site-Randomized Trial of Combined Cognitive Behavioral Therapy and Medication Management Algorithm for Treatment of Depression Among Youth With HIV in the United StatesLarry K Brown, Kristin Baltrusaitis, Betsy D Kennard, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 6, 2021
Site-Randomized Controlled Trial of a Combined Cognitive Behavioral Therapy and a Medication Management Algorithm for Treatment of Depression Among Youth Living With HIV in the United StatesLarry K Brown, Miriam Chernoff, Betsy D Kennard, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Journal of Graduate Medical Education|December 16, 2024
Diagnostic Stewardship Is Environmental StewardshipKristen Bastug, Ellen Townley, Laura Norton
The Pediatric Infectious Disease Journal|August 6, 2015
Safety, Pharmacokinetics and Efficacy of Dolutegravir in Treatment-experienced HIV-1 Infected Adolescents: Forty-eight-week Results from IMPAACT P1093Rolando M Viani, Carmelita Alvero, Terry Fenton, et al.
Antimicrobial Agents and Chemotherapy|July 18, 2002
Safety, pharmacokinetics, and pharmacodynamics of cyclodextrin itraconazole in pediatric patients with oropharyngeal candidiasisAndreas H Groll, Lauren Wood, Maureen Roden, et al.
AIDS (London, England)|May 20, 2024
Bridging dolutegravir clinical viral response across doses and formulations using model-based exposure-response analysis in pediatricsHardik Chandasana, Siobhán Hayes, Ann M Buchanan, et al.
Journal of the Pediatric Infectious Diseases Society|April 6, 2019
Long-Term Safety and Efficacy of Dolutegravir in Treatment-Experienced Adolescents With Human Immunodeficiency Virus Infection: Results of the IMPAACT P1093 StudyRolando M Viani, Theodore Ruel, Carmelita Alvero, et al.
Journal of Child and Adolescent Mental Health|November 17, 2024
Participant acceptability and clinician satisfaction of cognitive behavioural therapy and medication management algorithm compared with enhanced standard care for treatment of depression among youth with HIVEmily A Barr, Kristin Baltrusaitis, Betsy D Kennard, et al.
AIDS (London, England)|November 6, 2019
Pharmacokinetics and safety of a raltegravir-containing regimen in HIV-infected children aged 2-12 years on rifampicin for tuberculosisTammy Meyers, Pearl Samson, Edward P Acosta, et al.
Journal of the Pediatric Infectious Diseases Society|May 26, 2020
Pharmacokinetics and Safety of a Raltegravir-Containing Regimen in Children Aged 4 Weeks to 2 Years Living With Human Immunodeficiency Virus and Receiving Rifampin for TuberculosisPaul Krogstad, Pearl Samson, Edward P Acosta, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 15, 2022
Forty-Eight Week Outcomes of a Site-Randomized Trial of Combined Cognitive Behavioral Therapy and Medication Management Algorithm for Treatment of Depression Among Youth With HIV in the United StatesLarry K Brown, Kristin Baltrusaitis, Betsy D Kennard, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 6, 2021
Site-Randomized Controlled Trial of a Combined Cognitive Behavioral Therapy and a Medication Management Algorithm for Treatment of Depression Among Youth Living With HIV in the United StatesLarry K Brown, Miriam Chernoff, Betsy D Kennard, et al.
Pageof 3